US24661P8077 - Common Stock
DELCATH SYSTEMS INC
NASDAQ:DCTH (3/28/2024, 8:04:35 PM)
4.77
-0.32 (-6.29%)
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 52 full-time employees. The company went IPO on 2000-10-19. The firm is focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.
DELCATH SYSTEMS INC
1633 Broadway Ste 22C
New York City NEW YORK 10019
P: 12124892100
CEO: Gerard Michel
Employees: 52
Website: https://delcath.com/
DCTH stock results show that Delcath Systems beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Delcath Systems (NASDAQ:DCTH) just reported results for the fourth quarter of 2...
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and...
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...
Here you can normally see the latest stock twits on DCTH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: